Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study


Urun Y., Abali H., Turna H., Esin E., Sedef A. M. , Alkan A., et al.

European Cancer Congress, Vienna, Avusturya, 01 January 2015, cilt.51